Healthcare / Pharmaceutical RetailersTokyo
$1055.00
-64.00 (-5.72%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-223.0M · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$14.4B
P/E
10.7x
↓EV/EBITDA
6.0x
↓ROE
8.5%
↑Gross Margin
5.3%
↓Debt/Equity
0.46
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.9%
FCF CAGR
—
FCF margin
-3.5%
FCF / Net income
-4.61x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $349.45B · net income $2.64B · FCF $-12.16B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $349.45B | $349.45B | $334.66B | $304.44B | $278.16B |
| Net Income | $2.64B | $2.64B | $2.21B | $2.18B | $972.0M |
| EBITDA | $4.29B | $4.29B | $3.82B | $3.59B | $1.95B |
| EPS | 193.49 | 193.49 | 160.45 | 158.22 | 70.51 |
| Gross Margin | 5.3% | 5.3% | 5.1% | 5.2% | 4.9% |
| Operating Margin | 0.8% | 0.8% | 0.6% | 0.7% | 0.2% |
| Net Margin | 0.8% | 0.8% | 0.7% | 0.7% | 0.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.46 | 0.46 | 0.25 | 0.35 | 0.34 |
| Current Ratio | 1.14 | 1.14 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-12.16B | $-12.16B | $7.23B | $-223.0M | $1.17B |
| Returns | |||||
| ROE | 8.5% | 8.5% | 7.9% | 9.0% | 4.4% |
| Valuation | |||||
| P/E | 10.74 | 10.74 | 6.23 | 5.20 | 9.91 |
| EV/EBITDA | 5.99 | 5.99 | 3.25 | 4.61 | 7.36 |
| P/B | 0.46 | 0.46 | 0.49 | 0.47 | 0.44 |
| Growth & Yield | |||||
| Revenue Growth | 4.4% | 4.4% | 9.9% | 9.4% | — |
| EPS Growth | 20.6% | 20.6% | 1.4% | 124.4% | — |
| Dividend Yield | 2.7% | 2.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-21.5%
EPS terminal req.
$93.61
Spread vs growth
42.1%
5Y implied EPS CAGR
-10.2%
EPS terminal req.
$113.27
Spread vs growth
30.7%
10Y implied EPS CAGR
-0.6%
EPS terminal req.
$182.43
Spread vs growth
21.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-0.1%
Start / end P/E
6.8x → 5.5x
EPS bridge
160.45 → 193.49
Residual
-4.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.